Zhongguo quanke yixue (May 2022)
Comparison of Clinical Characteristics and Response to Glucocorticoid Therapy in Patients with Different Inflammatory Phenotypes of AECOPD and ACO
Abstract
Background Acute exacerbation is an important cause for the significant decline of lung function in patients with chronic airway disease, which seriously affects the health and quality of life of patients, and significantly increases the medical and economic burden of the disease. Early identification of different inflammatory phenotypes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and asthma-COPD overlap (ACO) and timely and precise treatment are important in reducing the occurrence of exacerbations, controlling disease progression, and improving quality of life. Objective To compare the clinical characteristics of AECOPD with different inflammatory phenotypes and ACO patients and their response to glucocorticoid therapy, and to provide a reference for further guiding the application of glucocorticoids. Methods The basic clinical data of AECOPD and ACO patients hospitalized in respiratory and critical care Medicine Department of the Second Hospital of Hebei Medical University from January 2018 to December 2020 were collected. The basic clinical data were collected, and the peripheral blood eosinophils (EOS) percentage (2%) was used as the critical value, EOS%≥2% was defined as EOS group, EOS%<2% was defined as non-EOS group, and ACO patients were defined as ACO group. The clinical characteristics and response to glucocorticoids of the three groups were analyzed. Results High-sensitivity C-reactive protein (hs-CRP) , absolute value of peripheral blood neutrophils (NE) , neutrophil/lymphocyte ratio (NLR) , fibrinogen/serum albumin (FAR) , lung and the use rate of systemic hormones, total hormone application, hormone treatment course, and hospitalization time of AECOPD patients in the EOS group were lower than those in the non-EOS group (P<0.05) . ALB of AECOPD patients in EOS group was higher than that in non-EOS group (P<0.05) . Body mass index (BMI) , FEV1%pred, severity of pulmonary function, absolute value of NE, NLR, utilization rate of pulmonary and systemic hormones, total hormone application, and hormone treatment course of AECOPD patients in the EOS group were lower than those in ACO group (P<0.05) . The age, hospitalization time, male prevalence rate, smoking rate, and EOS%≥2% of AECOPD patients in EOS group were higher than those in ACO group (P<0.05) . Conclusion EOS may be used as an important indicator to evaluate the severity of AECOPD and guide glucocorticoid therapy. The causes of acute exacerbations of COPD patients in the EOS group were mostly considered to be caused by non-infectious factors, and the treatment of antibiotics may be more prudent. AECOPD patients in EOS group have different clinical characteristics, and it is of positive significance to grasp their unique clinical characteristics for the early identification of chronic airway disease and accurate treatment decision.
Keywords
